All PlansCoverageMedium impact
Somatic Genetic Testing To Select Individuals with Melanoma or Glioma for Targeted Therapy (BRAF)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Neurology, Neurosurgery +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes coverage criteria for BRAF somatic genetic testing to guide targeted therapy selection for melanoma and glioma patients. The policy outlines FDA-approved companion diagnostic tests and targeted treatments, including specific BRAF inhibitors and combination therapies for patients with BRAF V600E/V600K mutations.
Action Required
Review current genetic testing orders for melanoma and glioma patients to ensure BRAF testing is appropriately ordered using FDA-approved companion diagnostic tests when targeted therapy is being considered. Verify that testing is limited to patients with unresectable or metastatic melanoma, or gliomas requiring systemic therapy. Document medical necessity for genetic testing in patient records.